Navigation Links
Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2009 Financial Results
Date:4/29/2009

Conference Call and Webcast Scheduled for Wednesday, May 6, 2009

SAN DIEGO, April 29 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its first quarter 2009 financial results after the Nasdaq market closes on Tuesday, May 5, 2009. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Wednesday morning, May 6, 2009 at 8:30 a.m. Eastern Daylight Time (5:30 a.m. Pacific Daylight Time).

Participants can access the live conference call by dialing 1-800-895-0198, (US) or 785-424-1053 (International) using the conference ID: 7NEURO. The call can also be accessed via the webcast through the Company's website at http://www.neurocrine.com

If you are unable to attend the Webcast and would like further information on this announcement please contact the Investor Relations Department at Neurocrine Biosciences at (858) 617-7600. A replay of the Conference Call will be available approximately one hour after the conclusion of the call by dialing 1-800-688-7339 (US) or 402-220-1347 (International) using the conference ID: 7NEURO. The call will be archived for two weeks.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, anxiety, depression, pain, diabetes, benign prostatic hyperplasia (BPH), irritable bowel syndrome (IBS) and other neurological and endocrine related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2008 Results
2. Webcast Alert: Neurocrine Announces 1Q08 Financial Results
3. Neurocrine Announces Closing of $109 Million Sale and Leaseback Agreement for its Real Estate Assets
4. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
5. Stem Cell Biotherapy Sues Casey Nabavi, Co-Founder and Former President, for Conduct Resulting in Claims by SCB Patients Against Nabavi, Embezzling Money and Converting Other Assets Belonging to SCB and for Wrongfully Establishing Cellulogix Biosciences t
6. Epiphany Biosciences Initiates Program to Assess Valomaciclovir (EPB-348) as Adjunctive Therapy in Multiple Sclerosis (MS)
7. Pressure BioSciences, Inc. Provides Corporate Update
8. BIND Biosciences To Install First Siemens Simatic(R) PCS 7 Lab Process Control System in the U.S.
9. Cell Biosciences Announces First UK System Sale
10. Regado Biosciences to Present at the 2009 Wharton Healthcare Business Conference
11. Enlight Biosciences Expands to direct up to $52 Million to Transformational Enabling Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2014)... WINSTON-SALEM, N.C. April 24, 2014 ,Take me ... of apple slices and kale chips. The more likely ... of Crackerjacks. , Unfortunately for children who play ... may be contributing to weight problems, according to researchers ... in the current online edition of Childhood Obesity ...
(Date:4/24/2014)... Richard Plemper, a professor in the new Institute ... received a five-year, $2.83 million federal grant to ... infection. , The grant from the Eunice Kennedy ... Development of the National Institutes of Health will ... anti-RSV drug and at least one distinct alternative ...
(Date:4/24/2014)... epidemic of prescription opioid overdose deaths was outlined yesterday ... by leaders of agencies in the U.S. Department of ... health care providers to expand their use of medications ... describes a number of misperceptions that have limited access ... how medications can be used in combination with behavior ...
(Date:4/24/2014)... the first in the world to discover a gene ... jaw. , Ameloblastoma is an odontogenic tumour with a ... often found in the posterior of the lower jaw. ... deficiencies in the jaws as well as loss of ... need for surgery and the recurrence of ameloblastoma, but ...
(Date:4/24/2014)... Foundation has awarded LSU Health Sciences Center New ... grant in the amount of $295,635. The funding ... social and educational backgrounds, underrepresented in the sciences, ... project will provide students with training for 10 ... will be led by Principal Investigator Dr. Fern ...
Breaking Medicine News(10 mins):Health News:Take the bat, leave the candy 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 3Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 4
... twins found that exposure to trichloroethylene (TCE) -- a ... -- is significantly associated with increased risk of Parkinson,s ... also linked to perchloroethylene (PERC) and carbon tetrachloride (CCI4) ... Annals of Neurology , a journal published by Wiley-Blackwell ...
... of the brain responsible for pain processing and ... following a medication holiday, say researchers from Georgetown ... indicate brain functioning is more streamlined after an ... is devoted to processing bothersome fibromyalgia perceptions such ...
... Diego School of Medicine and the UC San Diego ... approach enabling the destruction of the most highly proliferative ... issue of the journal Nature Medicine , points ... cells without causing some of the negative effects of ...
... , SUNDAY, Nov. 13 (HealthDay News) -- Unborn ... the heart transplant list before birth get new hearts more ... study. The findings are to be presented Tuesday ... After reviewing cases of fetal heart patients, including 46 ...
... , FRIDAY, Nov. 11 (HealthDay News) -- All ... be screened for high cholesterol, according to new guidelines endorsed ... are a major shift from current guidelines that suggest such ... history of heart disease or high blood cholesterol, which is ...
... will soon reduce reimbursements to some dialysis facilities, ... to drive further to get care at other ... People initiative provides 10-year national objectives for improving ... presents new kidney-related objectives., Two studies presented ...
Cached Medicine News:Health News:Parkinson's disease risk greater in those exposed to trichloroethylene 2Health News:Improved memory efficiency seen after aerobic exercise in fibromyalgia patients 2Health News:New way to target - and kill - proliferating tumors 2Health News:Babies Put on Transplant List Before Birth Get Hearts Faster 2Health News:New Guidelines Urge Cholesterol Check for All Kids Ages 9 to 11 2Health News:New Guidelines Urge Cholesterol Check for All Kids Ages 9 to 11 3Health News:New Guidelines Urge Cholesterol Check for All Kids Ages 9 to 11 4Health News:Kidney disease care -- what's in store for the future? 2
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
(Date:1/14/2014)... , Jan. 14, 2014 HeartWare International, Inc ... of less invasive, miniaturized circulatory support technologies that are ... that it expects revenues for the fourth quarter of ... 2013 revenues to approximately $208 million. "Our ...
(Date:1/14/2014)... North America,s leading business partnering event ... 30 th edition of its annual conference at the ... 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... specialty chemical companies will take part in the conference, which ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... July 19, 2011 Spanish drug companies face a ... the United States.  From regulatory (FDA) and GMP compliance, ... there are many areas that must be coordinated.  Those ... company KIM and U.S. company VPCI have entered into ...
... July 19, 2011 Reportlinker.com announces that ... in its catalogue: The ... Discovery http://www.reportlinker.com/p0574968/The-Changing-Role-of-Natural-Products-in-Drug-Discovery.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development ... This report reveals how natural products have ...
Cached Medicine Technology:Spanish Drug Companies Have New Support Option for the U.S. Market 2The Changing Role of Natural Products in Drug Discovery 2The Changing Role of Natural Products in Drug Discovery 3The Changing Role of Natural Products in Drug Discovery 4
Mayfield Disposable Adult (plastic) Skull Pins are designed for rigid skeletal fixation....
... borescopes are rigid endoscopes for general applications and ... The diameters of borescopes, i.e. rigid endoscopes, range ... directions from 0 up to a 120 retrospection, ... and wide angle view. Endoscopes with working lengths ...
Long system ventriculoscope for stereotactic frames....
... a new biological material produced ... collagen implant, lyoplant can absorb ... replacing implant material with the ... structure minimizes suture channels, resulting ...
Medicine Products: